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CD22 is a B-lym phocyte-specific glycoprotein that can function as an adhesion molecule c apable of binding multiple hemat opoietic cell types; it can also transduce signals to the cell int erior. Our studies have begun to dissect the CD22 signaling cascade at the biochemical level. We ident ified anti-CD22 monoclonal antibodies (mAb) that bind the two NH 2 -terminal immunoglobulin dom ains of CD22; these mAb specifically block the interaction of CD22 with its ligand. CD22-bl ocking mAb are highly effective at inducing proliferation of primary B-cells but the CD22 blocking mAb produce apoptotic responses in neoplastic B-cells (1) (2) (3) . Our lab and others have demonstrated that ligand blocking mAbs hav e distinct functional properties. We identified anti-CD22 mAbs that are unique and functionally distinguishable fr om other anti-B-cell, and even other anti-CD22 mAb (4) (5) (6) . In fact, the NCI has approved and funded the humanization of the anti-CD22 bloc king mAb, HB22.7 thr ough the Rapid Access Intervention Drug (RAID) Program. Humanized HB22.7 could become an exciting new therapy for patients with CD22-positive non-Hodgkin's lymphoma (NHL), much as rituximab (Rituxan) is an option to patients with CD20-positive NHL.
By sequencing the heavy and light chain variable regions of five anti-CD22 blocking mAbs, we identified highly conserved comp lementary determining regions (CDRs) that bind CD22, and initiate CD22-m ediated signal transduction. Anti-CD22 peptides were created based on the CDRs. We hypothes ize t hat these unique peptides d erived from the anti-CD22 mAb CDRs ca n be effective therapy against NHL and a utoimmune disease. Furthermore, we hypot hesize that the peptides that initia te signaling and enter B-cell NHL will b e the cornerstone for dev elopment of a CD22 -based drug deliver y system. Th ese novel, new anti-CD22 peptides may be even more effective than their parent mAbs, and the "next step" toward a new generation of effective anti-NHL drugs.
In addition, our understanding of CD22-medi ated signal transduction allows us to demonstrate that phos phatase inhibition can lead to enhanced CD22-mediated signals, apoptosis, and lymphomacidal effects in human NHL xenografts.
We also have the c apacity to use small animal immuno-positron emission tomography (iPET). IP ET is a new, sop histicated im aging s ystem that can fac ilitate our understanding of the NHL-target ing of these new drugs, and to rapidly enhance new drug development. Therefore, our Specific Aims are to:
II. Body
Progress within the first year of the grant ing period included ident ification and initial characterization of several CD22-binding p eptides which has been summarized in the year 1 progress report and recent publication (7) .
Below the research accomplish ments for year two will be sum marized and organize d based on the proposed aims and goals as outlined in the Statement of Work (SOW).
Aim I is to identify and characterize CD22-binding peptides that initiate signal transduction and results in apoptosis. CD22 binding and internalization will be optimized to enhance the highly specific and effective lymphomacidal properties demonstrated by the parent mAbs.
The goals of Aim I are: 2. The physiologic effects of high affinity peptides: initiation of signal transduction, and effects on cell growth and apoptosis, will be studied.
With regard to goal 2, significant p rogress has been made in this ar ea. We examined the signaling pa thways shown to be involved in CD22-mediat ede signalin g including the stre ss activated kinase (SAPK) and p38 (3) . Several immunoblotti ng (IB) exp eriments were done that demonstrated that both peptide 5 (previous characterized ) and peptide 44 both activate th e SAPK and p38 pathways, figure 1 . The IB was repeated three times with figure 1 being representative of all three experiments. 3. High affinity binding peptides will be further characterized by N and C-terminal deletion analysis and alanine walk analysis to identify the crucial amino acids for molecular recognition. Mutational analysis will be done to identify more peptides with enhanced affinity.
-Completed year 1
As propose d from the mutational analysis (7) we screen ed peptides for their a bility to kill lymphoma cells, figure 2. 
Cytotoxic Screening of CD22 Binding Peptides Screening in Ramos cells
Peptides #
As control ( % ) Figure 2 . CD22-binding peptides identified during the mutational analysis of peptide 5. Cell killing was assessed via trypan blue exclusion and reported as a percent of untreated control. Assays were done in triplicate with error bars representing standard deviation.
Promising peptides we selected based on their killin g potential and a co nfirmatory cytotoxicity assay was done, figure 3 .
Several promising peptides were identified t hat had greater killing potential th an the par ent, peptide 5. We next assessed if the killing wa s B cell specific, by assessing the killi ng potential in a maligna nt T cell line, Jurkat, figure 4. While the peptides did demonstrate some cyt otoxicty in T cells it was not of the same magnitude as that observed in B cells. These peptides were also effective at killing primary B cells and B cell specificity was confirmed. Goal: 4 . Promising peptides that initiate signal transduction and mediate apoptosis will be further assessed in vivo for their lymphomacidal properties using a nude mouse xenograft model.
CD22 Binding Peptides Treatment of Primary human B and T cells, Figure 7
We next assessed the ability of several of the peptides to mediate apoptosis in the Ramos B cell line, figure 8 This demonstrated effective inductio n of apoptosis with p eptide 5 which compared favorably to the targeted NHL therapeutic, Rituxan. This demonstrated that both peptide 5 and pep tide 41 effectively indu ced apoptosis to a gre ater extent than Rituxan.
While the binding poten tial of peptide 5 has previo usly been assessed, the binding potential of peptide 41 has not. Thus bead-bo und peptide 41 was assessed for its potential to bind Ramos B cells, figure 10 .
Rituxan

Peptidebeads #41 Untreated
Rituxan Peptidebeads #41 Untreated Figure 9 . Peptide 41 effectively induced apoptosis in Ramos cells. Cells we assessed as described in figure 8 .
This result was surprising as the majority of Ra mos cells did not bind t o the peptid e 41 coat ed beads, but repeate d studies ha s confirmed that it had B cell-specific cytotoxic effects and mediated apoptosis. Previous studies hav e demonstrated that peptide 5 blocked the binding of the anti-CD22 mAb HB22.7 to B cells.
Thus we used a flow cytometry-based assay to examine the effects of peptide 4 1 on HB22.7 binding to B cells, figure 11. This demonstrated that peptide 41 still partia lly blocked the binding of HB22.7 to Ra mos B cells suggesting that it ma y be transient ly binding to the CD22 ligand binding domain. We then hypothesized that peptide 41 ma y be mediating apoptosis b y transiently binding to B cells (? CD22), and mediating the secretion of a pro-apoptotic soluble factor. To test this hypothesis we used immobilized peptide 41 to mediate apoptosis in Ramos cells and then recovered the supernatant and subsequently incubated it with fresh Ramos B cells, figure 12. This demonstrated that peptide 41 mediated the secretion of a soluble factor that had cytotoxic potential in fresh Ramos cells.
Aim II is to optimize CD22-mediated signal transduction and the lymphomacidal properties of the ligand blocking anti-CD22 mAbs and peptides with CD22-specific phosphatase inhibition.
Goals for Aim II are:
To analyze CD22-mediated signal transduction and apoptosis manipulated by tyrosine phosphatase inhibition in vitro.
Previous st udies in o ur lab de monstrated that phosphatase in hibition wit h sodium orthovanidate (NaV) could augment CD22-med ited signal t ransduction, cytotoxicity and in vivo efficacy of the anti-CD22 mAb HB22.7 (8, 9) . As proposed we exa mined the effects of phosphatase inhibition on the cytotoxic potential of peptide 5, figure 13 Figure 13 . Ramos B cells were incubated with NaV at indicated concentrations with or without either HB22.7 (50 ug/cc) or peptide 5 (20uM) and assessed for cytotoxicity as described above Aim III: to correlate mAb-mediated and anti-CD22 peptide-mediated in vivo physiologic changes, efficacy, and tumor targeting using advanced iPET and FDG-PET imaging technology. The influence of phosphatase inhibitors will also be evaluated.
The goals for Aim 3 are:
1. To assess in vivo tumor metabolism by: FDG-PET imaging (which shows tumor metabolic activity), and iPET imaging (a highly sensitive method to assess in vivo tumor-targeting).
We have b egun to de velop the DOTA conj ugated peptides that will facilitat e the initial PET scan studies 2. To serially confirm and correlate the imaging data with the clinical effect (response rate) and in vitro physiologic effects (signaling, apoptosis) by using fine needle aspirates (FNA) and flow cytometry (FACS).
III. Annual Report Summary/Key Research Accomplishments
• Peptides 5 and 44 wer e found to activate the SAPK and p38 signal transduction pathways. • Based on t he mutational analysis of CD22 bin ding peptide 5 several a dditional peptides were identified that effectively kill lymphoma cells. • These pepti des (#40, 41, and 44) were shown to preferentially kill B cells, and their cytotoxic effects were dose responsive. • The cytotoxic effect s of peptide 41 was active in several NHL cell lin es that represent diverse NHL subtypes.
• Peptides 40, 41, and 44 killed normal as well as malignant B cells.
• Peptide 41 induced apoptosis in malignant B cells approximately to same degree as peptide 5 and considerably better than Rituxan. • We found that peptide 41 partially blocked binding of the anti-CD22 mAb HB22. 7 and thus likely binds to the same CD22 epitope and only binds transiently. • We demonstrated that peptide 4 1 mediated the produ ction of pr o-apoptotic soluble factors. • We demonstrated that phosphatase inhibition augmented the cytotoxic potential of peptide 5. • We have begun to develop DOTA-c onjugated peptide 5 and 41 in anticipation of immuno-PET studies.
IV. Reportable Outcomes
Currently th ere are no additional p ublications. The data presented ab ove is reportable but will only be published whe n verified and addition al data has been generated that will facil itate publication. All subsequent publications will acknowledge the DOD Investigator-Initiated Research Award Number (W81XWH-07-1-0471).
V. Conclusion
The studies presented herein demonstrate that a peptide derived fro m CDR2 of the anti-CD22 mAb HB22. 7 (Peptide 5) binds to CD22 on B lym phocytes, mediates internalization, signal transduction, and killing of lymphoma cells. We also demonstrated that this peptide can be used as a vehicle to deliver pro-apoptotic payload to lympho ma cell cell s that enhance the killing potential of the parent mAb and peptide (work completed in year 1). Studies completed in year 2 identified additional peptides (#40, 41, and 44) that were developed from the mutational analysis of peptide 5 that have been foun d to be even more effective at killing lympho ma cells an d inducing apoptosis. Interestingly these new peptides appear to mediate their cytotoxic effects by inducing malignant B cells to pro duce pro-apoptotic solu ble factors. Currently underway, or being planned are studies looking at the effectiveness of these peptides in a nude mouse model of human lymphoma, in vivo targeting using immuno-PET scanning, a nd the deve lopment o f additional modifications of the currently described peptides using combinatorial peptide libraries. We believe that these p eptides can be devel oped into exciting new highly effective and less toxic therapeutics for the treatment of lymphoma.
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